Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial

Marc E. Mooney, David V. Herin, Joy M. Schmitz, Nidal Moukaddam, Charles E. Green, John Grabowski

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Background: No medication is currently approved for the treatment of cocaine dependence, but several preclinical and clinical reports suggest agonist-like medications, e.g., amphetamine analogues, may be a productive strategy for medication development. Objective: This current proof-of-concept study sought to evaluate the safety, tolerability, and effectiveness of methamphetamine as a candidate treatment for cocaine dependence. Methods: A randomized, double-blind, placebo-controlled study served to evaluate three treatment conditions in 82 cocaine-dependent individuals: (1) placebo (0 mg, 6×/day; n = 27), (2) immediate release (IR) methamphetamine (5 mg, 6×/day; n = 30), (3) sustained release (SR) methamphetamine (30 mg first pill, 1×/day; 0 mg 5×/day; n = 25). The study employed a sequential, two-phase design (i.e., 4 weeks of medication and counseling followed by 4 weeks of medication/counseling plus a contingency management procedure). Results: Both preparation forms of methamphetamine were well-tolerated, with similar retention to placebo (0 mg, 33%; 30 mg IR, 30%, 30 mg SR, 32%). Methamphetamine SR was associated with decreased sleep and increased weight loss. Medication adherence rates were high for the first dose of the day (95%), while adherence for subsequent capsules was lower. Those in the SR condition exhibited consistently lower rates of cocaine-positive urine samples (0 mg, 60%; 30 mg IR, 66%; 30 mg SR, 29%), p < 0.0001, and reported the greatest reduction in craving for cocaine, p < 0.05. Conclusions: SR methamphetamine significantly reduced cocaine use and craving. Additional research is warranted to develop and evaluate agonist-like medications that may effectively treat cocaine dependence.

Original languageEnglish (US)
Pages (from-to)34-41
Number of pages8
JournalDrug and alcohol dependence
Volume101
Issue number1-2
DOIs
StatePublished - Apr 1 2009

Fingerprint

Methamphetamine
Cocaine
Placebos
Cocaine-Related Disorders
Counseling
Medication Adherence
Amphetamine
Capsules
Weight Loss
Sleep
Therapeutics
Urine
Safety
Research

Keywords

  • Agonist-like treatment
  • Cocaine
  • Dextroamphetamine
  • Methamphetamine

Cite this

Effects of oral methamphetamine on cocaine use : A randomized, double-blind, placebo-controlled trial. / Mooney, Marc E.; Herin, David V.; Schmitz, Joy M.; Moukaddam, Nidal; Green, Charles E.; Grabowski, John.

In: Drug and alcohol dependence, Vol. 101, No. 1-2, 01.04.2009, p. 34-41.

Research output: Contribution to journalArticle

Mooney, Marc E. ; Herin, David V. ; Schmitz, Joy M. ; Moukaddam, Nidal ; Green, Charles E. ; Grabowski, John. / Effects of oral methamphetamine on cocaine use : A randomized, double-blind, placebo-controlled trial. In: Drug and alcohol dependence. 2009 ; Vol. 101, No. 1-2. pp. 34-41.
@article{03885cf640aa45ae9dfa829534020dcb,
title = "Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial",
abstract = "Background: No medication is currently approved for the treatment of cocaine dependence, but several preclinical and clinical reports suggest agonist-like medications, e.g., amphetamine analogues, may be a productive strategy for medication development. Objective: This current proof-of-concept study sought to evaluate the safety, tolerability, and effectiveness of methamphetamine as a candidate treatment for cocaine dependence. Methods: A randomized, double-blind, placebo-controlled study served to evaluate three treatment conditions in 82 cocaine-dependent individuals: (1) placebo (0 mg, 6×/day; n = 27), (2) immediate release (IR) methamphetamine (5 mg, 6×/day; n = 30), (3) sustained release (SR) methamphetamine (30 mg first pill, 1×/day; 0 mg 5×/day; n = 25). The study employed a sequential, two-phase design (i.e., 4 weeks of medication and counseling followed by 4 weeks of medication/counseling plus a contingency management procedure). Results: Both preparation forms of methamphetamine were well-tolerated, with similar retention to placebo (0 mg, 33{\%}; 30 mg IR, 30{\%}, 30 mg SR, 32{\%}). Methamphetamine SR was associated with decreased sleep and increased weight loss. Medication adherence rates were high for the first dose of the day (95{\%}), while adherence for subsequent capsules was lower. Those in the SR condition exhibited consistently lower rates of cocaine-positive urine samples (0 mg, 60{\%}; 30 mg IR, 66{\%}; 30 mg SR, 29{\%}), p < 0.0001, and reported the greatest reduction in craving for cocaine, p < 0.05. Conclusions: SR methamphetamine significantly reduced cocaine use and craving. Additional research is warranted to develop and evaluate agonist-like medications that may effectively treat cocaine dependence.",
keywords = "Agonist-like treatment, Cocaine, Dextroamphetamine, Methamphetamine",
author = "Mooney, {Marc E.} and Herin, {David V.} and Schmitz, {Joy M.} and Nidal Moukaddam and Green, {Charles E.} and John Grabowski",
year = "2009",
month = "4",
day = "1",
doi = "10.1016/j.drugalcdep.2008.10.016",
language = "English (US)",
volume = "101",
pages = "34--41",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Effects of oral methamphetamine on cocaine use

T2 - A randomized, double-blind, placebo-controlled trial

AU - Mooney, Marc E.

AU - Herin, David V.

AU - Schmitz, Joy M.

AU - Moukaddam, Nidal

AU - Green, Charles E.

AU - Grabowski, John

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Background: No medication is currently approved for the treatment of cocaine dependence, but several preclinical and clinical reports suggest agonist-like medications, e.g., amphetamine analogues, may be a productive strategy for medication development. Objective: This current proof-of-concept study sought to evaluate the safety, tolerability, and effectiveness of methamphetamine as a candidate treatment for cocaine dependence. Methods: A randomized, double-blind, placebo-controlled study served to evaluate three treatment conditions in 82 cocaine-dependent individuals: (1) placebo (0 mg, 6×/day; n = 27), (2) immediate release (IR) methamphetamine (5 mg, 6×/day; n = 30), (3) sustained release (SR) methamphetamine (30 mg first pill, 1×/day; 0 mg 5×/day; n = 25). The study employed a sequential, two-phase design (i.e., 4 weeks of medication and counseling followed by 4 weeks of medication/counseling plus a contingency management procedure). Results: Both preparation forms of methamphetamine were well-tolerated, with similar retention to placebo (0 mg, 33%; 30 mg IR, 30%, 30 mg SR, 32%). Methamphetamine SR was associated with decreased sleep and increased weight loss. Medication adherence rates were high for the first dose of the day (95%), while adherence for subsequent capsules was lower. Those in the SR condition exhibited consistently lower rates of cocaine-positive urine samples (0 mg, 60%; 30 mg IR, 66%; 30 mg SR, 29%), p < 0.0001, and reported the greatest reduction in craving for cocaine, p < 0.05. Conclusions: SR methamphetamine significantly reduced cocaine use and craving. Additional research is warranted to develop and evaluate agonist-like medications that may effectively treat cocaine dependence.

AB - Background: No medication is currently approved for the treatment of cocaine dependence, but several preclinical and clinical reports suggest agonist-like medications, e.g., amphetamine analogues, may be a productive strategy for medication development. Objective: This current proof-of-concept study sought to evaluate the safety, tolerability, and effectiveness of methamphetamine as a candidate treatment for cocaine dependence. Methods: A randomized, double-blind, placebo-controlled study served to evaluate three treatment conditions in 82 cocaine-dependent individuals: (1) placebo (0 mg, 6×/day; n = 27), (2) immediate release (IR) methamphetamine (5 mg, 6×/day; n = 30), (3) sustained release (SR) methamphetamine (30 mg first pill, 1×/day; 0 mg 5×/day; n = 25). The study employed a sequential, two-phase design (i.e., 4 weeks of medication and counseling followed by 4 weeks of medication/counseling plus a contingency management procedure). Results: Both preparation forms of methamphetamine were well-tolerated, with similar retention to placebo (0 mg, 33%; 30 mg IR, 30%, 30 mg SR, 32%). Methamphetamine SR was associated with decreased sleep and increased weight loss. Medication adherence rates were high for the first dose of the day (95%), while adherence for subsequent capsules was lower. Those in the SR condition exhibited consistently lower rates of cocaine-positive urine samples (0 mg, 60%; 30 mg IR, 66%; 30 mg SR, 29%), p < 0.0001, and reported the greatest reduction in craving for cocaine, p < 0.05. Conclusions: SR methamphetamine significantly reduced cocaine use and craving. Additional research is warranted to develop and evaluate agonist-like medications that may effectively treat cocaine dependence.

KW - Agonist-like treatment

KW - Cocaine

KW - Dextroamphetamine

KW - Methamphetamine

UR - http://www.scopus.com/inward/record.url?scp=60249094085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249094085&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2008.10.016

DO - 10.1016/j.drugalcdep.2008.10.016

M3 - Article

C2 - 19058926

AN - SCOPUS:60249094085

VL - 101

SP - 34

EP - 41

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1-2

ER -